Better Pain Management Through Better Data Act of 2018
USA115th CongressHR-5473| House
| Updated: 6/13/2018
Barbara Comstock
Republican Representative
Virginia
Cosponsors (6)
Health, Education, Labor, and Pensions Committee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Better Pain Management Through Better Data Act of 2018 This bill directs the Food and Drug Administration (FDA) to update or issue guidance for drug sponsors on data collection related to the use of other pain medication to reduce the need for opioids. The guidance must address alternative methods for data collection, product labeling, and investigations other than clinical trials.
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Ordered to be Reported by Voice Vote.
Committee Consideration and Mark-up Session Held.
Mr. Walden moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H5031-5032)
DEBATE - The House proceeded with forty minutes of debate on H.R. 5473.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5031-5032)
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5031-5032)
Motion to reconsider laid on the table Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Health
Administrative law and regulatory proceduresConsumer affairsDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationDrug trafficking and controlled substancesHealth information and medical recordsPrescription drugsPublic participation and lobbying
Better Pain Management Through Better Data Act of 2018
USA115th CongressHR-5473| House
| Updated: 6/13/2018
Better Pain Management Through Better Data Act of 2018 This bill directs the Food and Drug Administration (FDA) to update or issue guidance for drug sponsors on data collection related to the use of other pain medication to reduce the need for opioids. The guidance must address alternative methods for data collection, product labeling, and investigations other than clinical trials.
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Ordered to be Reported by Voice Vote.
Committee Consideration and Mark-up Session Held.
Mr. Walden moved to suspend the rules and pass the bill, as amended.
Considered under suspension of the rules. (consideration: CR H5031-5032)
DEBATE - The House proceeded with forty minutes of debate on H.R. 5473.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5031-5032)
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5031-5032)
Motion to reconsider laid on the table Agreed to without objection.
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Barbara Comstock
Republican Representative
Virginia
Cosponsors (6)
Health, Education, Labor, and Pensions Committee, Energy and Commerce Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Administrative law and regulatory proceduresConsumer affairsDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationDrug trafficking and controlled substancesHealth information and medical recordsPrescription drugsPublic participation and lobbying